Cencora Earnings Call Transcripts
Fiscal Year 2026
-
Strong U.S. segment growth and expanded MSO capabilities drove increased guidance, while strategic acquisitions and divestitures enhanced operational focus. Specialty and generics markets remain healthy, with ongoing investments in synergies, contracting, and customer relationships supporting long-term growth.
-
Strong U.S. segment growth and raised guidance followed the OneOncology acquisition, with ongoing MSO strategy execution and a robust pipeline of generics and biosimilars supporting long-term growth. Capital deployment is focused on de-leveraging, with future M&A limited to bolt-on specialty investments.
-
The meeting covered director elections, executive compensation, and auditor ratification, all of which passed by majority vote. Financial results showed 16% growth in adjusted operating income and EPS, with new acquisitions and a $1 billion investment commitment announced.
-
Delivered strong Q1 FY26 results with 12% adjusted operating income growth and 9% EPS growth, completed OneOncology acquisition, and raised full-year guidance for revenue and operating income. U.S. Healthcare Solutions led performance, with MSO expansion and specialty focus driving growth.
-
Strong revenue and profit growth driven by specialty pharmaceuticals, MSO expansion, and strategic investments. Raised long-term guidance following acquisitions and continued focus on digital transformation, productivity, and global logistics. Regulatory and market trends remain manageable.
Fiscal Year 2025
-
Strong fiscal 2025 results and raised long-term guidance reflect robust specialty and MSO growth, with continued investment in innovation and capital deployment. International operations are being streamlined, and key client relationships remain stable. Biosimilars and GLP-1s offer margin opportunities, while capital is balanced across investments, acquisitions, and shareholder returns.
-
Strong specialty market growth, MSO expansion, and strategic capital deployment are driving robust operating income and long-term guidance. Full ownership of OneOncology and digital transformation are expected to enhance synergies and efficiency, while regulatory advocacy and evolving market trends support continued outperformance.
-
Strong fiscal 2025 results featured 16% adjusted operating income and EPS growth, driven by specialty focus and strategic investments. Long-term guidance was raised, with continued infrastructure expansion and portfolio optimization, despite headwinds from a major customer loss and PharmaLex impairment.
-
Fiscal 2025 guidance was raised multiple times, driven by strong US specialty performance and strategic acquisitions. Specialty and biosimilars remain key growth drivers, while international operations face headwinds from subdued clinical trial activity. Capital deployment and digital transformation are strategic priorities.
-
Operating income growth guidance was raised significantly, driven by strong US performance and the RCA acquisition. Strategic focus remains on growth investments, MSOs, and technology, while international operations show early signs of stabilization. Free cash flow will support further investments, acquisitions, and shareholder returns.
-
Strong U.S. specialty and healthcare segments drove robust profit growth and raised EPS guidance. Margin expansion outpaced revenue due to business mix, with biosimilars and RCA contributing. International recovery and capital deployment for acquisitions and tech investment are key 2026 priorities.
-
Q3 saw strong 21% operating income and 20% EPS growth, led by U.S. Healthcare Solutions and specialty. Full-year guidance for EPS and operating income was raised, with RCA acquisition and digital investments fueling margin gains. International segment faces headwinds but is expected to recover.
-
Management highlighted resilience to policy changes, strong specialty and core distribution growth, disciplined inventory and OpEx management, and a focus on MSO expansion and biosimilar adoption. Capital deployment remains balanced, with major investments planned for specialty growth.
-
Q2 saw 10% revenue and 16% adjusted EPS growth, driven by U.S. specialty strength and RCA integration. Full-year EPS and operating income guidance were raised, while international segment outlook was trimmed due to clinical trial softness. Capital deployment focuses on MSO expansion and deleveraging.
-
Raised EPS guidance on strong U.S. healthcare momentum, with specialty and biosimilar growth driving results. Long-term contracts and strategic investments in oncology and retina support future expansion, while capital deployment remains balanced.
-
Q1 saw 13% revenue and 14% adjusted EPS growth, driven by U.S. Healthcare Solutions and strong GLP-1 sales. Full-year guidance was raised for EPS and revenue, with RCA acquisition boosting specialty leadership. COVID-19 headwinds persist, but broad-based growth and strategic investments support a positive outlook.
-
The event highlighted a continued focus on specialty and higher-margin businesses, recent strategic investments, and robust financial performance. Ongoing productivity initiatives and digital transformation are set to drive efficiency, while M&A and international expansion remain key growth levers. Strong customer relationships and resilient independent pharmacy support underpin the outlook.
Fiscal Year 2024
-
Specialty product sales and biosimilar launches are expected to drive growth in FY 2025, with operating income guided at 5%-6.5% despite COVID vaccine headwinds. Strategic partnerships, international expansion, and technology investments support long-term value, while capital allocation remains balanced.
-
Strong financial performance was highlighted by a successful $1.8B bond issuance, robust specialty and MSO growth, and resilient margins despite regulatory uncertainty. Strategic focus remains on specialty expansion, customer partnerships, and innovation in services and therapies.
-
Adjusted EPS grew 15% for the year and 17% in Q4, with revenue up 12% to $294B, driven by specialty and GLP-1 products. Announced RCA acquisition expands MSO capabilities; FY25 guidance projects 8–10% EPS growth, with COVID headwinds and major customer loss factored in.
-
Fiscal 2024 EPS guidance was raised, with 2025 set at the lower end of long-term targets due to COVID normalization and a potential customer loss. Key contracts were extended, specialty markets and biosimilars remain growth drivers, and the CEO transition is expected to maintain strategic continuity.
-
Fiscal 2024 guidance was raised on strong U.S. performance, while 2025 growth is expected at the low end of long-term targets due to declining COVID contributions and a potential customer loss. Specialty, biosimilars, and international services are key growth drivers, with balanced capital deployment supporting future expansion.
-
Leadership transition ensures strategic continuity, with a raised 2024 EPS outlook and 2025 growth expected at the lower end of guidance due to COVID normalization and contract expirations. Specialty, international, and animal health segments show strong performance, while long-term customer and supply agreements provide stability.
-
Quarterly revenue grew 11% to $74.2B and adjusted EPS rose 14% to $3.34, driven by strong US Healthcare Solutions performance and specialty product sales. Fiscal 2024 guidance was raised for EPS, revenue, and free cash flow, while a leadership transition to Bob Mauch as CEO was announced.